...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of neuropsychiatry and clinical neurosciences >The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study.
【24h】

The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study.

机译：文拉法辛与喹硫平联合治疗难治性抑郁症的临床研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The authors studied the efficacy and safety of combined venlafaxine and quetiapine treatment for treatment-resistant depression (TRD) by dividing 95 TRD patients into two treatment groups: a combined venlafaxine (225 mg/day) and quetiapine (400 mg/day) group and a venlafaxine-only (225 mg/day) group for 8 weeks. Efficacy was assessed with the Hamilton Rating Scale for Depression, 17 items (Ham-D-17) and the Hamilton Rating Scale for Anxiety (Ham-A); safety was assessed with the Treatment-Emergent Symptom Scale (TESS). The two groups showed significant differences for the Ham-D-17 and Ham-A and no differences on the TESS. Combined venlafaxine and quetiapine treatment showed good efficacy and safety in TRD.
机译：作者通过将95位TRD患者分为两个治疗组研究了文拉法辛与喹硫平联用治疗难治性抑郁症（TRD）的有效性和安全性：文拉法辛（225 mg /天）和喹硫平（400 mg /天）联合治疗组和一个仅使用文拉法辛的药物（225毫克/天），治疗8周。用汉密尔顿抑郁量表（Ham-D-17）和汉密尔顿焦虑量表（Ham-A）评估疗效。安全性用治疗紧急症状量表（TESS）进行评估。两组的Ham-D-17和Ham-A表现出显着差异，而TESS则无差异。文拉法辛与喹硫平联合治疗在TRD中显示出良好的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号